

- Childress MA, Himmelberg SM, Chen H, Deng W, Davies MA and Lovly CM (2018). ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. *Mol Cancer Res*. 2018 Jul 12. doi: 10.1158/1541-7786.MCR-18-0171. [Epub ahead of print]
- Park YL, Kim HP, Cho YW, Min DW, Cheon SK, Lim YJ, Song SH, Jin Kim S, Han SW, Park KJ and Kim TY (2018). Activation of WNT/ β -catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. *Int J Cancer*. 2018 Jul 6. doi: 10.1002/ijc.31662. [Epub ahead of print]
- McDaniel NK, Cummings CT, Iida M, Hulse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, Harari PM, Kimple RJ, DeRyckere D, Graham DK and Wheeler DL (2018). MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. *Mol Cancer Ther*. 2018 Aug 9. pii: molcanther.1239.2017. doi: 10.1158/1535-7163.MCT-17-1239. [Epub ahead of print]
- Greaves G, Milani M, Butterworth M, Carter RJ, Byrne DP, Eyers PA, Luo X, Cohen GM and Varadarajan S (2018). BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL. *Cell Death Differ*. 2018 Sep 5. doi: 10.1038/s41418-018-0183-7. [Epub ahead of print]
- Yan D, Parker RE, Wang X, Frye SV, Earp HS 3rd, DeRyckere D and Graham DK (2018). MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members. *Clin Cancer Res*. 2018 Sep 7. doi: 10.1158/1078-0432.CCR-18-0040. [Epub ahead of print]
- Liu B, Han D, Zhang T, Cheng G, Yinliang L, Wang J, Zhao H and Zhao Z (2018). Hypoxia-induced autophagy promotes EGFR loss in specific cell contexts, which leads to cell death and enhanced radiosensitivity. *Int J Biochem Cell Biol*. 2018 Sep 29. pii: S1357-2725(18)30206-1. doi: 10.1016/j.biocel.2018.09.013. [Epub ahead of print]
- Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL and Neal DE (2018). Identification of potential therapeutic targets in prostate cancer through a cross-species approach. *EMBO Mol Med*. 2018 Feb 5. pii: e8274. doi: 10.15252/emmm.201708274. [Epub ahead of print]
- Rizzotto L, Lai TH, Bottoni A, Woyach JA, Lapalombella R, Bloomfield CD, Byrd JC and Sampath D (2018). Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. *Leuk Lymphoma* 59(6), 1461-1465
- Turcato F, Kim P, Barnett A, Jin Y, Scerba M, Casey A, Selman W, Greig NH and Luo Y (2018). Sequential combined Treatment of Pifithrin- α and Posiphen Enhances Neurogenesis and Functional Recovery After Stroke. *Cell Transplant* 27(4), 607-621
- Rizvi I, Obaid G, Bano S, Hasan T and Kessel D (2018). Photodynamic therapy: Promoting in vitro efficacy of photodynamic therapy by liposomal formulations of a photosensitizing agent. *Lasers Surg Med* 50(5), 499-505
- Lin M, Zhang X, Jia B and Guan S (2018). Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2. *J Neurooncol* 136(2), 243-254
- Dompe N, Klijn C, Watson SA, Leng K, Port J, Cuellar T, Watanabe C, Haley B, Neve R, Evangelista M and Stokoe D (2018). A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. *PLoS One* 13(6):e0199264
- Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfar S, Al-Rawi A, Yadav V, Qin L, Nanda S, Sethunath V, Fu X, De Angelis C, Narkar VA, Osborne CK, Schiff R and Trivedi MV (2018). GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. *Breast Cancer Res Treat* 170(2), 279-292
- Niklaus NJ, Humbert M and Tschan MP (2018). Cisplatin sensitivity in breast cancer cells is associated with particular DMTF1 splice variant expression. *Biochem Biophys Res Commun* 503(4), 2800-2806
- Gong C, Valduga J, Chateau A, Richard M, Pellegrini-Moïse N, Barberi-Heyob M, Chastagner P and Boura C (2018). Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1. *Oncotarget* 9(20), 15312-15325
- Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT and Rudin CM (2018). Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts. *Clin Cancer Res* 24(20), 5143-5152
- Koh SB, Walley Z, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM and Jodrell DI (2018). Mechanistic Distinctions between CHK1 and ATR Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. *Cancer Res* 78(11), 3054-3066
- Walley Z, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quirós Fernández S, Lau A, Richards FM and Jodrell DI (2018). The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression. *Mol Cancer Ther* 17(8), 1670-1682
- Ha JR, Ahn R, Smith HW, Sabourin V, Hébert S, Cepeda Cañedo E, Im YK, Kleinman CL, Muller WJ and Ursini-Siegel J (2018). Integration of Distinct ShcA Signaling Complexes Promotes Breast Tumor Growth and Tyrosine Kinase Inhibitor Resistance. *Mol Cancer Res* 16(5), 894-908
- Chen X, Legrand AJ, Cunniffe S, Hume S, Poletto M, Vaz B, Ramadan K, Yao D and Dianov GL (2018). Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients. *Cell Oncol* 41(5), 527-539
- Rodriguez-Berriguete G, Granata G, Puliyadi R, Tiwana G, Prevo R, Wilson RS, Yu S, Buffa F, Humphrey TC, McKenna WG and Higgins GS (2018). Nucleoporphin 54 contributes to homologous recombination repair and post-replicative DNA integrity. *Nucleic Acids Res* 46(15), 7731-7746
- Jung MY1, Kang JH1, Hernandez DM1, Yin X1, Andrianifahanana M1, Wang Y2, Gonzalez-Guerrico A3, Limper AH1, Lupu R3, Leaf EB (2018). Fatty acid synthase is required for proinflammatory TGF- β signaling. *FASEB J* 32(7), 3803-3815
- Wang H, Zhang C, Chi H and Meng Z (2018). Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. *Mol Med Rep* 17(6), 8101-8110
- Sabatella M, Theil AF, Ribeiro-Silva C, Slysokva J, Thijssen K, Voskamp C, Lans H and Vermeulen W (2018). Repair protein persistence at DNA lesions characterizes XPB defect with Cockayne syndrome features. *Nucleic Acids Res* 46(18), 9563-9573
- Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, Zhang D, Horton J, Reuben JM, McMurray JS and Woodward WA (2018). Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. *Int J Radiat Oncol Biol Phys*. 100(4), 1034-1043
- Rhysans GW, Yao Y, Zhang J, Dulak A, Castriotta L, Jacques K, Zhao W, Gharahdaghi F, Hattersley MM, Lyne PD, Clark E, Zinda M, Fawell SE, Mills GB and Chen H (2018). BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. *PLoS One* 13(7):e0200826
- Houschek J, Ritter V, Wirsdörfer F, Klein D, Jendrossek V and Matschke J (2018). Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia. *Cancer Lett* 439, 24-38
- Houschek J, Hansel C, Jendrossek V and Matschke J (2018). The Mitochondrial Citrate Carrier (SLC25A1) Sustains Redox Homeostasis and Mitochondrial Metabolism Supporting Radioresistance of Cancer Cells With Tolerance to Cycling Severe Hypoxia. *Front Oncol*. 8:170
- Ha JR, Ahn R, Smith HW, Sabourin V, Hébert S, Cepeda Cañedo E, Im YK, Kleinman C, Muller WJ and Ursini-Siegel J (2018). Integration of distinct ShcA signaling complexes promotes breast tumor growth and tyrosine kinase inhibitor resistance. *Mol Cancer Res* 16(5), 894-908
- Xu H, Wang T, Yang C, Li X, Liu G, Yang Z, Singh PK, Krishnan S and Ding D (2018). Supramolecular Nanofibers of Curcumin for Highly Amplified Radiosensitization of Colorectal Cancers to Ionizing Radiation. *Adv Funct Mater* 2018, 1707140. https://doi.org/10.1002/adfm.201707140
- Piscitello D, Varshney D, Lilla S, Vizioli MG, Reid C, Gorbunova V, Seluanov A, Gillespie DA and Adams PD3 (2018). AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11. *Oncogene* 37(4), 427-438
- Carter RJ, Nickson CM, Thompson JM, Kacperek A, Hill MA and Parsons JL (2018). Complex DNA Damage Induced by High Linear Energy Transfer Alpha-Particles and Protons Triggers a Specific Cellular DNA Damage Response. *Int J Radiat Oncol Biol Phys* 100(3), 774-784
- Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y and Plunkett W (2018). Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. *Cancer Chemother Pharmacol* 81(2), 255-267
- Young MA, Daly CS, Taylor E, James R, Clarke AR and Reed KR (2018). Subtle Deregulation of the Wnt-Signaling Pathway Through Loss of Apc2 Reduces the Fitness of Intestinal Stem Cells. *Stem Cells* 36(1), 114-122
- Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M and Harrington KJ (2017). Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. *Mol Cancer Ther* 16(1), 25-34
- Jayakumar S, Patwardhan RS, Pal D, Singh B, Sharma D, Kutala VK and Sandur SK (2017). Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity. *Free Radic Biol Med* 113, 530-538
- Choy L, Hagenbeek TJ, Solon M, French D, Finkle D, Shelton A, Venook R, Brauer MJ and Siebel CW (2017). Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers. *Cancer Res* 77(6), 1439-1452
- Han Y, Ren J, Lee E, Xu X, Yu W and Muegge K (2017). Lsh/HELLS regulates self-renewal/proliferation of neural stem/progenitor cells. *Sci Rep* 7(1), 1136
- Eskra JN, Kuiper JW, Walden PD, Bosland MC and Özten N (2017). Interactive effects of 9-cis-retinoic acid and androgen on proliferation, differentiation, and apoptosis of LNCaP prostate cancer cells. *Eur J Cancer Prev* 26(1), 71-77
- Polosukhina D, Love HD, Moses HL, Lee E, Zent R and Clark PE (2017). Pharmacologic Inhibition of β -Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor. *Oncol Res* 25(9), 1653-1664
- Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F and Oritura M (2017). Phosphatidylinositol 3-kinase (PI3K)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. *Oncotarget* 8(44), 76479-76491
- Mandemakers IK, van Cuijk L, Janssens RC, Lans H, Bezstarosti K, Hoeijmakers JH, Demmers JA, Vermeulen W and Martelijn JA (2017). DNA damage-induced histone H1 ubiquitylation is mediated by HUWE1 and stimulates the RNF8-RNF168 pathway. *Sci Rep* 7(1), 15353
- Naidu S, Shi L, Magee P, Middleton JD, Laganá A, Sahoo S, Leong HS, Galvin M, Frese K, Dive C, Guzzardo V, Fassan M and Garofalo M (2017). PDGFR-mediated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF- κ B pathways. *Sci Rep* 7(1), 15441
- Fitzpatrick PA, Akrap N, Söderberg EMV, Harrison H, Thomson GJ and Landberg G (2017). Robotic Mammography Assay for High-Throughput Screening in Triple-Negative Breast Cancer. *SLAS Discov* 22(7), 827-836
- Jiang M, Zhuang H, Xia R, Gan L, Wu Y, Ma J, Sun Y and Zhuang Z (2017). KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells. *Oncotarget* 8(54), 92106-92118
- Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA and Ince TA (2017). Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. *Oncogene*. 36(12), 1707-1720
- Espindola-Netto JM, Chini CCS, Tarragó M, Wang E, Dutta S, Pal K, Mukhopadhyay D, Sola-Penna M and Chini EN (2017). Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. www.impactjournals.com/oncotarget/ *Oncotarget*. *Advance Publications* 2017
- Schwarz LJ, Hutchinson KE, Brent N, Rexer BN et al (2017). An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. *JNCI* 109(11) dxj065, <https://doi.org/10.1093/jnci/djx065>
- Mazzu YZ, Hu Y, Soni RK, Mojica KM, Qin LX, Agius P, Waxman ZM, Mihailovic A, Socci ND, Hendrickson RC, Tuschl T and Singer S (2017). miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells. *Cancer Res*. 77(21), 5728-5740
- Chen C, Wang X, Fang J, Xue J, Xiong X, Huang Y, Hu J and Ling K (2017). EGFR-induced phosphorylation of type Iy phosphatidylinositol phosphate kinase promotes pancreatic cancer progression. *Oncotarget* 8(26), 42621-42637
- Li C, Singh B, Graves-Deal R, Ma H, Starchenko A, Fry WH, Lu Y, Wang Y, Bogatcheva G, Khan MP, Milne GL, Zhao S, Ayers GD, Li N, Hu H, Washington MK, Yeatman TJ, McDonald OG, Liu Q, Coffey RJ (2017). Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. *Proc Natl Acad Sci U S A*. 114(14), E2852-E2861
- Matsuki M, Adachi Y, Ozawa Y, Kimura T, Hoshi T, Okamoto K, Tohyama O, Mitsuhashi K, Yamaguchi A, Matsui J and Funahashi Y (2017). Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. *Cancer Sci* 108(4), 763-771
- Rinaldi F, Del Favero E, Rondelli V, Pieretti S, Bogni A, Ponti J, Rossi F, Di Marzio L, Paolino D, Marianecchi C and Carafa M (2017). pH-sensitive niosomes: Effects on cytotoxicity and on inflammation and pain in murine models. *J Enzyme Inhib Med Chem* 32(1), 538-546
- Gallenne T, Ross KN, Visser NL, Salony, Desmet CJ, Wittner BS, Wessels LFA, Ramaswamy S and Peeper DS (2017). Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer. *Oncotarget* 8(13), 20572-20587
- Choy L, Hagenbeek TJ, Solon M, French D, Finkle D, Shelton A, Venook R, Brauer MJ and Siebel CW (2017). Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers. *Oncotarget* 8(13), 20572-20587
- Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN 3rd, Zent R and Clark PE (2017). Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. *Mol Oncol* 11(4), 405-421
- Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP et al (2017). EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. www.impactjournals.com/oncotarget/ *Oncotarget*, *Advance Publications* 2017

- Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishaivan MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES and Arteaga CL (2017). Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. *Cancer Res* 77(9), 2488-2499
- Han Y, Ren J, Lee E, Xu X, Yu W and Muegge K (2017). Lsh/HELLS regulates self-renewal/proliferation of neural stem/progenitor cells. *Sci Rep* 7(1), 1136
- Yu H, Jiang Y, Liu L, Shan W, Chu X, Yang Z and Yang ZQ (2017). Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer. *Oncotarget* 8(8), 13099-13115
- Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, Wang J, Gray NS, Dalby KN, Bartholomew S, Ueno NT (2017). c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. *Oncogene* 36(18), 2599-2608
- Voss DM, Spina R, Carter DL, Lim KS, Jeffery CJ and Bar EE (2017). Disruption of the monocarboxylate transporter-4-basinin interaction inhibits the hypoxic response, proliferation, and tumor progression. *Sci Rep* 7(1), 4292Tanei T, Choi DS, Rodriguez AA, Liang DH, Dobrolecki L, Caceres S, Peña L, Lacerda L, Illera MJ, de Andres PJ, Larson RA, Gao H, Debeb BG, Woodward WA, Reuben JM and Illera JC (2017). Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer. *Vet Comp Oncol* 15(3), 980-995
- Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhhattar R, Young RA and Ince TA (2017). Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. *Oncogene* 36(12), 1707-1720
- Lanfredini S, Olivero C, Borgogna C, Calati F, Powell K, Davies KJ, De Andrea M, Harries 1, Tang HKC, Pfister H, Gariglio M and Patel GK (2017). HPV8 Field Cancerization in a Transgenic Mouse Model Is due to Lrig1+ Keratinocyte Stem Cell Expansion. *J Invest Dermatol* 137(10), 2208-2216
- Kessel D and Reiners JJ Jr (2017). Effects of Combined Lysosomal and Mitochondrial Photodamage in a Non-small-Cell Lung Cancer Cell Line: The Role of Paraptosis. *Photochem Photobiol* 93(6), 1502-1508
- Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D and Puduvali VK (2017). Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. *Clin Cancer Res* 23(20), 6215-6226
- Li T, Wang Z, Hou YF and Li YY (2017). Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway. *J Cancer* 8(9), 1530-1541
- Baba Y, Tamura T, Satoh Y, Gotou M, Sawada H, Ebara S, Shibuya K, Soeda J and Nakamura K (2017). Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. *Mol Oncol* 11(8), 1065-1077
- Kessel D (2017). Subcellular Targeting as a Determinant of the Efficacy of Photodynamic Therapy. *Photochem Photobiol* 93(2), 609-612
- Murai S, Ando A, Ebara S, Hirayama M, Satomi Y and Hara T (2017). Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions. *Oncogenesis* 6(5), e329
- Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessou R, Kogan L, Baloch T, Gottlieb WH and Yasmeen A (2017). Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. *BMC Cancer* 17(1), 638
- Shan W, Jiang Y, Yu H, Huang Q, Liu L, Guo X, Li L, Mi Q, Zhang K and Yang Z (2017). HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer. *Am J Cancer Res* 7(5), 1213-1226
- Ha YJ, Tak KH, Kim CW, Roh S1, Choi EK, Cho DH, Kim JH, Kim SK, Kim SY5, Kim YS and Kim JC (2017). PSMB8 as a Candidate Marker of Responsiveness to Preoperative Radiation Therapy in Rectal Cancer Patients. *Int J Radiat Oncol Biol Phys* 98(5), 1164-1173
- Feng F, Cheng Q, Yang L, Zhang D, Ji S, Zhang Q, Lin Y, Li F, Xiong L, Liu C and Jiang X (2017). Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing. *Oncotarget* 8(3), 5349-5360
- Nickson CM, Moorj P, Carter RJ, Rubbi CP and Parsons JL (2017). Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity. *Oncotarget* 8(18), 29963-29975
- Walko G, Woodhouse S, Pisco AO, Rognoni E, Liakath-Ali K, Lichtenberger BM, Mishra A, Telesman SB, Viswanathan P, Logtenberg M, Renz LM, Donati G, Quist SR and Watt FM (2017). A genome-wide screen identifies YAP/WBP2 interplay conferring growth advantage on human epidermal stem cells. *Nat Commun* 8:14744
- Hilmi K, Jangal M, Marques M, Zhao T, Saad A, Zhang C, Luo VM, Syme A, Rejon C, Yu Z, Krum A, Fabian MR, Richard S, Alaoui-Jamali M, Orthwein A, McCaffrey L and Witcher M (2017). CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair. *Sci Adv* 3(5), e1601898
- Gupta A, Anjomani-Virmouni S, Koundouros N, Dimitriadis M, Choo-Wing R, Valle A, Zheng Y, Chiu YH, Agnihotri S, Zadeh G, Asara JM, Anastasiou D, Arends MJ, Cantley LC and Poulougiannis G (2017). PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. *Mol Cell* 65(6), 999-1013
- Ondracek J, Fadrus P, Sana J, Besse A, Loja T, Vecera M, Radova L, Smrcka M, Slampa P and Slaby O (2017). Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells. *Anticancer Res* 37(3), 1099-1104
- Thomas JD, Longen CG, Oyer HM, Chen N, Maher CM, Salvino JM, Kania B, Anderson KN, Ostrander WF, Knudsen KE and Kim FJ (2017). Sigma 1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. *Cancer Res* 77(9), 2439-2452
- Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M and Harrington KJ (2017). Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. *Mol Cancer Ther* 16(1), 25-34
- Edmonds MJ, Carter RJ, Nickson CM, Williams SC and Parsons JL (2017). Ubiquitylation-dependent regulation of NELL1 by Mule and TRIM26 is required for the cellular DNA damage response. *Nucleic Acids Research* 45(2), 726-738
- Hou Z, Gattoc L, O'Connor C, Yang S, Wallace-Povirk A, George C, Orr S, Polin L, White K, Kushner J, Morris RT, Gangjee A and Matherly LH (2017). Dual targeting of epithelial ovarian cancer via folate receptor α and the proton-coupled folate transporter with 6-substituted pyrrolo[2,3-d]pyrimidine antifolates. *Mol Cancer Ther* 16(5), 819-830
- Kessel D (2017) Sequential vs. simultaneous photokilling by mitochondrial and lysosomal photodamage. *Proc SPIE 10047, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXVI, 1004702 (February 8, 2017); doi:10.1117/1.2251207*
- Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hymann DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J and Arteaga CL (2017). An Acquired HER2/T981 Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. *Cancer Discov* 7(6), 575-585
- Sharma A and Capobianco E (2017). Immuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes. *Cancer Inform* 16:1176935117721691
- Khan S, Oosterhuis K, Wunderlich K, Bunick EM, Bhaggoe M, Boedhoe S, Karia S, Steenberg RDM, Bosch L, Serroyen J, Janssen S, Schuitemaker H, Vellinga J, Scheper G, Zahn R and Custers J (2017). Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease. *Int J* 141(2), 393-404
- Starchenko A, Graves-Deal R, Yang YP, Li C, Zent R, Singh B and Coffey RJ (2017). Clustering of integrin $\alpha 5$ at the lateral membrane restores epithelial polarity in invasive colorectal cancer cells. *Mol Biol Cell* 28(10), 1288-1300
- Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, Phung TL, Mani SA, Stossi F, Sreekumar A, Mancini MA, Decker WK, Zong C, Lewis MT and Zhang XH (2017). Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. *Nature* 544(7649), 250-254
- Ghosh M, Landis MD and Chang JC (2016). Antitumor activity of Cetuximab in combination with ixabepilone on triple negative breast cancer stem cells. *Breast Cancer Research* 18:6
- Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, Stratford M, Muschel RJ, Higgins GS, McKenna WG (2016). The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. *Nat Commun* 7:12308
- Welte T, Kim IS, Tian L, Gao X, Wang H, Li J, Holdman XB, Herschkowitz JI, Pond A, Xie G, Kurley S, Nguyen T, Liao L, Dobrolecki LE, Pang L, Mo Q, Edwards DP, Huang S, Xin L, Xu J, Li Y, Lewis MT, Wang T, Westbrook TF, Rosen JM and Zhang XH (2016). Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. *Nat Cell Biol* 18(6), 632-44
- Behnan J, Grieg Z, Joel M, Ramsness I and Stangland B (2016). Gene knockdown of CENPA reduces sphere forming ability and stemness of glioblastoma initiating cells. *Neuroepigenetics* 7 (2016) 6-18
- Thakkar A, Wang B, Picon-Ruiz M, Buchwald P and Ince TA (2016). Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. *Breast Cancer Res Treat* 157(1), 77-90
- Tanei T, Choi DS, Rodriguez AA, Liang DH, Dobrolecki L, Ghosh M, Landis MD and Chang JC (2016). Antitumor activity of Cetuximab in combination with ixabepilone on triple negative breast cancer stem cells. *Breast Cancer Res* 18(1), 6
- Smith DL, Debeb BG, Thames HD and Woodward WA (2016). Computational Modeling of Micrometastatic Breast Cancer Radiation Dose Response. *Int J Radiat Oncol Biol Phys* 96(1), 179-87
- Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS and Arteaga CL (2016). Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. *Sci Transl Med* 8(334), 334ra53
- Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR and Arteaga CL (2016). Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. *Cancer Res* 76(2), 440-52
- Kierulff-Vieira KS, Sandberg CJ, Grieg Z, Günther CC, Langmoen IA and Vik-Mo EO (2016). Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation. *Exp Cell Res* 340(1), 53-61
- Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM and Gorski DH (2016). Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. *Breast Cancer Res Treat* 157(2), 217-28
- Gonzalez-Guerrico AM, Espinoza I, Schroeder B, Park CH, Kyp CM, Khurana A, Corominas-Faja B, Cuyàs E, Alarcón T, Kleer C, Menendez J and Lupu R (2016). Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer. *Oncotarget* 7(44), 71151-71168
- Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX, Lee JZ, Tan BJ, Shyh-Chang N, Lim EH, Lim WT, Tan DS, Tan EH, Tai BC, Soo RA, Tam WL and Lim B (2016). Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. *Nat Commun* 7:11702
- Keller KC, Ding H, Tieu R, Sparks NR, Ehnes DD and zur Nieden N (2016). Wnt5a Supports Osteogenic Lineage Decisions in Embryonic Stem Cells. *Stem Cells Dev* 25(13), 1020-32
- Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang F, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J and Böglor O (2016). Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. *J Transl Med* 14:46
- Zhang Y, Cabarcas SM, Zheng J, Sun L, Mathews LA, Zhang X, Lin H and Farrar WL (2016). Cryptotanshinone targets tumor-initiating cells through down-regulation of stemness genes expression. *Oncol Lett* 11(6), 3803-3812
- Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, Al Fayi MS, Al-Jameel W, Rudland PS, Hussain SA and Ke Y (2016). Fatty acid activated PPAR α promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. *Oncotarget* 7(8), 9322-39
- Saud SM, Li W, Gray Z, Matter MS, Colburn NH, Young MR and Kim YS (2016). Diallyl Disulfide (DADS), a Constituent of Garlic, Inactivates NF- κ B and Prevents Colitis-Induced Colorectal Cancer by Inhibiting GSK-3 β . *Cancer Prev Res (Phila)* 9(7), 607-15
- Andrianifahanana M, Hernandez DM, Yin X, Kang JH, Jung MY, Wang Y, Yi ES, Roden AC, Limper AH and Leaf EB (2016). Probiotic up-regulation of glucose transporter 1 by TGF- β involves activation of MEK and mammalian target of rapamycin complex 2 pathways. *FASEB J* 30(11), 3733-3744
- Liberante FG, Pouryahya T, McMullin MF, Zhang SD and Mills KI (2016). Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. *Oncotarget* 7(6), 6609-19
- Thorenor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M and Slaby O (2016). Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer. *Oncotarget* 7(1), 622-37
- Ichikawa K, Miyano SW, Adachi Y, Matsuki M, Okamoto K, et al. (2016). Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways. *Glob J Cancer Ther* 2(1), 019-025.
- Matschke J, Riffkin H, Klein D, Handrick R, Lüdemann L, Metzen E, Shlomi T, Stuschke M and Jendrosseck V (2016). Targeted inhibition of glutamine-dependent glutathione metabolism overcomes death resistance induced by chronic cycling hypoxia. *Antioxid Redox Signal*. 25(2), 89-10
- Manton CA, Johnson B, Singh M, Bailey CP, Bouchier-Hayes L and Chandra J (2016). Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. *Sci Rep*. 6, 18953.
- Park JH, Vithayathil S, Kumar S, Sung PL, Dobrolecki LE, Putluri V, Bhat VB, Bhowmik SK, Gupta V, Arora K, Wu D, Tsouko E, Zhang Y, Maity S, Danti TR, Graham BH, Frigo DE, Coarfa C, Yotnda P, Putluri N, Sreekumar A, Lewis MT, Creighton JC, Wong LJ and Kaiparettu BA (2016). Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. *Cell Rep* 14(9), 2154-65
- Kessel D and Evans CL (2016). Promotion of Proapoptotic Signals by Lysosomal Photodamage: Mechanistic Aspects and Influence of Autophagy. *Photochem Photobiol* 92(4), 620-3

- Lynam-Lennon N, Bibby BA, Mongan AM, Marignol L, Paxton CN, Geiersbach K, Bronner MP, O'Sullivan J, Reynolds J and Maher SG (2016). Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma. *Mol Med* 22
- Matschke J, Wiebeck E, Hurst S, Rudner J and Jendrossek V (2016). Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia. *Radiat Oncol* 11:75
- Kim JA, Tan Y, Wang X, Cao X, Veerarraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R and Wang XS (2016). Comprehensive functional analysis of the tousel-like kinase 2 frequently amplified in aggressive luminal breast cancers. *Nat Commun*. 7:12991
- Matschke J, Wiebeck E, Hurst S, Rudner J and Jendrossek V (2016). Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia. *Radiat Oncol*. 11:75
- Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM and Gorski DH (2016). Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. *Breast Cancer Res Treat* 157(2), 217-228
- Kotschy A et al. (2016). The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. *Nature* 538(7626), 477-482
- Chini CC1, Espindola-Netto JM2, Mondal G1, Guerrico AM1, Nin V1, Escande C1, Sola-Penna M3, Zhang JS4, Billadeau DD4, Chini EN (2016). SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. *Clin Cancer Res* 22(10), 2496-507
- Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK (2016). The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. *JCI Insight* 1(3), e85630
- Shinde A, Berhane H, Rhiue BH, Kalash R, Xu K, Goff J, Epperly MW, Francicola D, Zhang X, Dixon T, Shields D, Wang H, Wipf P, Parmar K, Guinan E, Kagan V, Tyurin V, Ferris RL, Zhang X, Li S and Greenberger JS (2016). Intraoral Mitochondrial-Targeted GS-Nitroxide, JP4-039, Radioprotects Normal Tissue in Tumor-Bearing Radiosensitive Fancd2(-/-) (C57BL/6) Mice. *Radiat Res* 185(2), 134-50
- Sufit A, Lee-Sherick AB, DeRyckere D, Rupji M, Dwivedi B, Varella-Garcia M, Pierce AM, Kowalski J, Wang X, Frye SV, Earp HS, Keating AK and Graham DK (2016). MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. *PLoS One* 11(10), e0165107
- Vermeer DW, Coppock JD, Zeng E, Lee KM, Spanos WC, Onken MD, Uppaluri R, Lee JH and Vermeer PD (2016). Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis. *Oncotarget* 7(17), 24194-207
- Gill MR, Harun SN, Halder S, Boghoozian RA, Ramadan K, Ahmad H and Vallis KA (2016). A ruthenium polypyridyl intercalator stalls DNA replication forks, radiosensitizes human cancer cells and is enhanced by Chk1 inhibition. *Sci Rep* 6, 31973
- Haider S, McIntyre A, van Stiphout RG, Winchester LM, Wigfield S, Harris AL and Buffa FM (2016). Genomic alterations underlie a pan-cancer metabolic shift associated with tumour hypoxia. *Genome Biol* 17(1), 140
- Hahn ER, Singh KB and Singh SV (2016). c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. *Cell Cycle* 15(17), 2309-20
- den Hollander P, Rawls K, Tsimelzon A, Shepherd J, Mazumdar A, Hill J, Fuqua SA, Chang JC, Osborne CK, Hilsenbeck SG, Mills GB and Brown PH (2016). Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. *Cancer Res*. 76(7), 1942-53
- Uboldi C, Urbán P, Gilliland D, Bajak E, Valsami-Jones E, Ponti J and Rossi F (2016). Role of the crystalline form of titanium dioxide nanoparticles: Rutile, and not anatase, induces toxic effects in Balb/3T3 mouse fibroblasts. *Toxicol In Vitro* 31, 137-45
- Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Khadimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC and Kilgour E (2016). Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon. *PLoS One* 11(2), e0149628
- S Chini CC, Espindola-Netto JM, Mondal G, Guerrico AM, Nin V, Escande C, Sola-Penna M, Zhang JS, Billadeau DD and Chini EN (2015). IRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. *Clin Cancer Res* 22(10), 2496-507
- Mughal AA, Grieg Z, Skjellegrind H, Fayzullin A, Lamkhannat M, Joel M, Ahmed MS, Murrell W, Vik-Mo EO, Langmoen IA and Stangeland B (2015). Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells. *Mol Cancer*. 14:160
- Buchner M, Park E, Geng H, Klemm L, Flach J, Passetgué E, Schjerven H, Melnick A, Paietta E, Kopanja D, Raychaudhuri P and Mischen M (2015). Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. *Nat Commun*. 6:6471
- Park AK, Francis JM, Park WY, Park JO and Cho J (2015). Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. *Oncotarget* 6(11), 8839-50
- Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz C, Ueno NT and Rao A (2015). Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. *J Cancer* 6(12), 1306-19
- Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS and Graham DK (2015). Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. *Oncotarget* 6(9), 6722-36
- Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB and Brown PH (2015). Death-associated protein kinase 1 promotes growth of p53-mutant cancers. *J Clin Invest* 125(7), 2707-20
- Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R and Fagin JA (2015). NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. *Cancer Discov* 5(11), 1178-93
- Durinck S, Stawiski EW, Pavia-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillary J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiramam V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas A and Seshagiri S (2015). Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. *Nat Genet* 47(1), 13-21
- Zhao XD, Lu YY, Guo H, Xie HH, He LJ, Shen GF, Zhou JF, Li T, Hu SJ, Zhou L, Han YN, Liang SL, Wang X, Wu KC, Shi YQ, Nie YZ and Fan DM (2015). MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis. *J Cell Biol* 210(4), 613-27
- Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dabbin A, Lee J, Saso H, Smith PD, Dalby KN and Ueno NT (2015). MEK inhibitor selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. *Mol Cancer Ther* 14(12), 2773-81
- Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S and Ueno NT (2015). Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. *Mol Cancer Ther* 14(12), 2687-99
- Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ and Khabele D (2015). Aberrant overexpression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. *Oncotarget* 6(25), 21353-68
- Joel M, Mughal AA, Grieg Z, Murrell W, Palmero S, Mikkelsen B, Fjordingstad HB, Sandberg CJ, Behnan J, Glover JC, Langmoen IA and Stangeland B (2015). Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. *Mol Cancer*. 14:121
- Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH, Manoharan V, Ong EH, Sangthongpitag K, Hill J, Petretto E, Keller TH, Lee MA, Matter A and Virshup DM (2015). Wnt addition of genetically defined cancers reversed by PORCN inhibition. *Oncogene* 35(17), 2197-207
- Gallant JN, Sheehan JA, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J and Lovly CM (2015). EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. *Cancer Discov*. 5(11), 1155-63
- Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolny F, Makker V, Sala E, Soumerai TE, Hyman DM, Succi ND, Viale A, Gershenson DM2, Farley J, Levine DA, Rosen N, Berger MF, Spriggs DR, Aghajanian CA, Solit DB and Iyer G (2015). Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. *J Clin Oncol* 33(34), 4099-105
- Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, Klimowicz A, Tonin PN, Buchanan M, Keilty D, Hassan S, Laperrière D, Mader S, Aleynikova O and Basik M (2015). The estrogen receptor cofactor SPEN functions as a tumor suppressor and candidate biomarker of drug responsiveness in hormone-dependent breast cancers. *Cancer Res* 75(20), 4351-63
- Wilkes MC, Repellin CE, Kang JH, Andrianifanana M, Yin X and Leaf EB (2015). Sorting Nexin 9 Differentiates Ligand-activated Smad3 from Smad2 for Nuclear Import and TGFβ Signaling. *Mol Biol Cell*. 26(21), 3879-91
- Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meing T, Murrell W, Vik Mo EO, Langmoen IA (2015). Combined expression analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells. *Oncotarget*. 6(28), 26192-215
- Liu H, Liu L, Holowatyj A, Jiang Y and Yang ZQ (2015). Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. *Mol Carcinog*. May;55(5):977-990
- Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT and Woodward WA (2015). High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. *Int J Radiat Oncol Biol Phys* 91(5), 1072-80
- Debeb BG, Smith DL, Li L, Larson R, Xu W and Woodward WA (2015). Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer. *PLoS One* 10(3), e0120719
- Chen H, Lee J, Klijavin NM, Haley B, Daemen A, Johnson L and Liang Y (2015). Requirement for BUB1/BUBR1 in tumor progression of lung adenocarcinoma. *Genes Cancer*. 6(3-4), 106-18
- Li W, Saud SM, Young MR, Colburn NH and Hua B (2015). Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro. *Mol Cell Biochem* 406(1-2), 63-73
- Yoshida T, Kim JH, Carver K, Su Y, Weremowicz S, Mulvey L, Yamamoto S, Brennan C, Mei S, Long H, Yao J and Polyak K (2015). CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. *Cancer Res* 75(7), 1516-26
- Venditti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT and Rudin CE (2015). Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. *Oncotarget* 6(1), 56-70
- Petersson F, Del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Siegel PM and Miller WH Jr (2015). Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. *Cancer Res* 75(6), 1102-12
- Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T and Yang ZQ (2015). Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. *Am J Cancer Res*. 5(4):1519-30
- Scanu T, Spaepen RM, Bakker JM, Pratap CB, Wu L, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, Song J-Y, Neeffes-Borst EA, Riele H te, Holden DW, Nath G and Neeffes J (2015). Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma. *Cell Host & Microbe* 17, 1 - 12
- Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Yi B, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY and Yu Q (2015). IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. *Nat Commun*. 6:8746
- Serguieiko A, Grad I, Wennerström AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O and Munthe E (2015). Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. *Oncotarget* 6(4), 2451-65
- Nencini A, Prатели C, Quinn JM, Salerno M, Tunici P, De Robertis A, Valensin S, Mennillo F, Rossi M, Bakker A, Benicchi T, Cappelli F, Turliczi E, Nibbio M, Caradonna NP, Zanelli U, Andreini M, Magnani M and Varrone M (2015). Structure-activity relationship and properties optimization of a series of quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway. *Eur J Med Chem* 95, 526-45
- Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS and Chang JC (2015). Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. *Breast Cancer Res*. 17:25
- Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dabbin A, Lee J, Saso H, Smith PD, Dalby KN and Ueno NT (2015). MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. *Mol Cancer Ther*. 14(12), 2773-81
- Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK, Pizzo SV and Bachelder RE (2015). Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance. *Breast Cancer Res*. 17:91
- Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL and Owens P (2015). Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. *Cancer Lett* 368(1):79-87
- Wang B, Lee CW, Witt A, Thakkar A and Ince TA (2015). Heat shock factor 1 induces cancer stem cell phenotype in breast cancer cell lines. *Breast Cancer Res Treat* 153(1), 57-66

- Amin O, Beauchamp MC, Nader PA, Laskov I, Iqbal S, Philip CA, Yasmeen A and Gotlieb WH (2015). Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors. *BMC Cancer* 15:817
- French R, Hayward O, Jones S, Yang W and Clarkson R (2015). Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL. *Mol Cancer* 14, 209
- Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, Hajdich M, Sachlova M, Svoboda M and Slaby O (2015). MIR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. *Tumour Biol* 37(6), 8007-18
- Kessel D and Reiners JJ Jr (2015). Promotion of Proapoptotic Signals by Lysosomal Photodamage. *Photochem Photobiol* 91(4), 931-6
- Ahmed SU, Carruthers R, Gilmour L, Yildirim S, Watts C and Chalmers AJ (2015). Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells. *Cancer Res* 75(20), 4416-28
- Boersma V, Moatti N, Segura-Bayona S, Peuscher MH, van der Torre J, Wevers BA, Orthwein A, Durocher D and Jacobs JJ (2015). MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' end resection. *Nature* 521(7553), 537-40
- Farcal L, Torres Andón F, Di Cristo L, Rotoli BM, Bussolati O, Bergamaschi E, Mech A, Hartmann NB, Rasmussen K, Riego-Sintes J, Ponti J, Kinsner-Ovaskainen A, Rossi F, Oomen A, Bos P, Chen R, Bai R, Chen C, Rocks L, Fulton N, Ross B, Hutchison G, Tran L, Mues S, Ossig R, Schneckeburger J, Campagnolo L, Vecchione L, Pietrouisti A and Fadel B (2015). Comprehensive In Vitro Toxicity Testing of a Panel of Representative Oxide Nanomaterials: First Steps towards an Intelligent Testing Strategy. *PLoS One* 10(5), e0127174
- Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorne W, Tindall DJ, Lewis JS and Sawyers CL (2015). Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. *Cancer Res* 75(22), 4688-96
- Davies BR, Guan N, Logie A, Crafter C, Hanson L, Jacobs V, James N, Dudley P, Jacques K, Ladd B, D'Cruz CM, Zinda M, Lindemann J, Kodaira M, Tamura K and Jenkins EL (2015). Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. *Mol Cancer Ther* 14(11), 2441-5
- O'Brien SK, Chen L, Zhong W, Armellino D, Yu J, Loreth C, Follettie M and Damelin M (2015). Breast cancer cells respond differentially to modulation of TGF- β 2 signaling after exposure to chemotherapy or hypoxia. *Cancer Res* 75(21):4605-16
- Koumangoye RB, Andl T, Taubenslag KJ, Zilberman ST, Taylor CJ, Loomans HA and Andl (2015). SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. *Mol Cancer* 14:24
- Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS and Graham DK (2015). Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status. *Mol Cancer Ther* 14(9), 2014-22
- Randriarimanana T, Chateau A, Faivre B, Pinel S and Boura C (2015). Sensitivity of glioma initiating cells to a monoclonal anti-EGFR antibody therapy under hypoxia. *Life Sci* 137, 74-80
- Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ and Turner NC (2015). Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. *Mol Cancer Ther* 14(4), 865-76
- Bartholomeusz C and Esteve FJ (2015). CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. *Breast Cancer Res Treat* 151(3), 501-13
- Bibby BA, Reynolds JV and Maher SG (2015). MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. *PLoS One* 10(7), e0134180
- Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC and Esteve FJ (2015). HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. *Mol Oncol* 9(3), 586-600
- Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM and Burger A (2015). Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer. *PLoS One* 10(3), e0119614
- Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB and Ladanyi M (2015). MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. *Clin Cancer Res* 21(8), 1935-43
- Deorukhkar A, Ahuja N, Mercado AL, Diagaradjane P, Raju U, Patel N, Mohindra P, Diep N, Guha S and Krishnan S (2015). Zerbombone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation. *Cancer Med* 4(2), 278-92
- Colbert PL, Vermeer DW, Wiekling BG, Lee JH and Vermeer PD (2015). EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity. *Oncotarget* 6(2), 953-68
- Naipal KA, Raams A, Bruens ST, Brandsma I, Verkaik NS, Jaspers NG, Hooijmakers JH, van Leenders GJ, Pothof J, Kanaar R, Boormans J and van Gent DC (2015). Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer. *PLoS One* 10(4), e0126029
- Carruthers R, Ahmed SU, Strathdee K, Gomez-Roman N, Amoah-Buahin E, Watts C and Chalmers AJ (2015). Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. *Mol Oncol* 9(1), 192-203
- Ha YJ, Kim CW, Roh SA, Cho DH, Park JL, Kim SY, Kim JH, Choi EK, Kim YS and Kim JC (2015). Epigenetic regulation of KLHL34 predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients. *Int J Radiat Oncol Biol Phys* 91(3), 650-8
- Guest ST, Kratchke ZR, Bollig-Fischer A, Haddad R, Ethier SP (2015). Two members of the TRIC chaperonin complex, CCT2 and TCP1 are essential for survival of breast cancer cells and are linked to driving oncogenes. *Exp Cell Res* 332(2), 223-35
- Pappano WN, Guo J, He Y, Ferguson D, Jagadeeswaran S, Osterling DJ, Gao W, Spence JK, Plushchev M, Sweis RF, Buchanan FG, Michaelides MR, Shoemaker AR, Tse C and Chiang GG (2015). The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia. *PLoS One* 10(7), e0131716
- Goldmacher VS, Audette CA, Guan Y, Sidhom EH, Shah JV, Whiteman KR, and Kovtun YV (2015). High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction. *PLoS One* (2), e0117523
- Bajak E, Fabbri M, Ponti J, Gioria S, Ojea-Jiménez I, Collotta A, Mariani V, Gilliland D, Rossi F and Gribaldo L (2015). Changes in Caco-2 cells transcriptome profiles upon exposure to gold nanoparticles. *Toxicol Lett* 233(2), 187-99
- Tiwana GS, Prevo R, Buffa FM, Yu S, Ebner DV, Howarth A, Folkes LK, Budwal B, Chu KY, Durrant L, Muschel RJ, McKenna WG and Higgins GS (2015). Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen. *Oncotarget* 6(8), 5978-89
- Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC and Ethier SP (2014). KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. *Neoplasia* 16(8), 644-55
- Schwarz LJ, Fox EM, Balco JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM and Arteaga CL (2014). LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. *J Clin Invest* 124(12), 5490-502
- Patki M, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepko G and Ratnam M (2014). Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed. *J Thorac Oncol* 9(4), 519-26
- Yong JW, Choong ML, Wang S, Wang Y, Lim SQ and Lee MA (2014). Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient. *Cancer Cell Int* 14(1), 94
- Sun Q, Cibas ES, Huang H, Hodgson L and Overholtzer M (2014). Induction of entosis by epithelial cadherin expression. *Cell Res* 24(11), 1288-98
- Zhang B, Zhang B, Chen X, Bae S, Singh K, Washington MK, and Datta PK (2014). Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. *Br J Cancer*. 2014 Feb 18;110(4), 946-57
- Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Nigro CL, Carroll J, Coombes RC, Bevan C, Ali S and Palmieri C (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. *Breast Cancer Res Treat* 147(2):295-309
- Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P and Ueno NT (2014). A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. *Breast Cancer Res Treat* 146(2), 259-72
- Li C, Ma H, Wang Y, Cao Z, Graves-Deal R, Powell AE, Starchenko A, Ayers GD, Washington MK, Kamath V, Desai K, Gerdes MJ, Solnica-Krezel L and Coffey RJ (2014). Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer. *J Clin Invest* 124(5), 2172-87
- Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J (2014). JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. *Cancer Res* 74(9), 2444-54
- Choong ML, Yong J, Wang Y and Lee MA (2014). Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene. *Biores Open Access* 3(4), 176-82
- Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ and Neve RM (2014). Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes. *Cancer Res* 74(11), 3114-26
- Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O and Munthe E (2014). Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines. *PLoS One* 9(8), e103873
- Blackmore JK1, Karmakar S, Gu G, Chaubal V, Wang L, Li W and Smith CL (2014). The SMRT Coregulator Enhances Growth of Estrogen Receptor- α -Positive Breast Cancer Cells by Promotion of Cell Cycle Progression and Inhibition of Apoptosis. *Endocrinology* 155(9), 3251-61
- Mannino M, Gomez-Roman N, Hochegger H and Chalmers AJ (2014). Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. *Stem Cell Res* 13(1), 135-43
- Chen D, Forootan SS, Gosney JR, Forootan FS and Ke Y (2014). Increased expression of Id1 and Id3 promotes tumorigenicity by enhancing angiogenesis and suppressing apoptosis in small cell lung cancer. *Genes Cancer* 5(5-6), 212-25
- Murphy AJ, Pierce J, de Caestecker C, Ayers GD, Zhao A, Krebs JR, Saito-Diaz VK, Lee E, Perantoni AO, de Caestecker MP and Lovvorn HN 3rd (2014). CITED1 confers stemness to Wilms tumor and enhances tumorigenic responses when enriched in the nucleus. *Oncotarget* 5(2), 386-402
- Chini CC, Gonzalez Guerrero A, Nin V, Camacho-Pereira J, Escande C, Barbosa M and Chini EN (2014). Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. *Clin Cancer Res* 20(1):120-30
- Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi J, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ and Arteaga CL (2014). Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. *Cancer Discov* 4(2), 232-45
- Jaganathan H, Gage J, Leonard F, Srinivasan S, Souza GR, Dave B and Godin B (2014). Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation. *Sci Rep* 1(4), 6468
- Wei W, Twardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM and Lewis MT (2014). STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. *Stem Cells* 32(10), 2571-82
- Arasada RR, Amann JM, Rahman MA, Huppert SS and Carbone DP (2014). EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. *Cancer Res* 74(19):5572-84
- Wei W, Twardy DJ, Zhang M, Zhang X, Landua J, Petrovic I, Bu W, Roarty K, Hilsenbeck SG, Rosen JM and Lewis MT (2014). STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. *Stem Cells* 32(10):2571-82
- Jaganathan H, Mitra S, Srinivasan S, Dave B, Godin B (2014). Design and in vitro evaluation of layer by layer siRNA nanovectors targeting breast tumor initiating cells. *PLoS One* 9(4), e91986
- Chen G, Kong J, Tucker-Burden C, Anand M, Rong Y, Rahman F, Moreno CS, Van Meir EG, Hadjipanayis CG, Brat DJ (2014). Human Brat Ortholog TRIM3 Is a Tumor Suppressor That Regulates Asymmetric Cell Division in Glioblastoma. *Cancer Res* 74(16), 4536-48
- Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Li X, Gilcrease M, Lai Z, Chen Y, Huang TH, Shen H, Liu X, Ferrari M, Zhan M, Wong ST, Kumaraswami M, Mittal V, Chen X, Gross SS and Chang JC (2014). Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. *Proc Natl Acad Sci USA* 111(24), 8838-43
- Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, Jia L, Colburn NH and Young MR (2014). Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. *Mol Carcinog*. 54(10), 1096-109
- Kessel D and Reiners JJ Jr (2014). Enhanced efficacy of photodynamic therapy via a sequential targeting protocol. *Photochem Photobiol* 90 (4), 889-95
- Shinde A, Epperly MW, Cao S, Holt D, Goff J, Shields D, Franicola D, Wipf P, Wang H and Greenberger JS (2014). Improved hematopoiesis in GS-nitroide (JP4-039)-treated mouse long-term bone marrow cultures and radioresistance of derived bone marrow stromal cell lines. *In Vivo* 28(5), 699-708
- Smyth T, Paraiso KH, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, Sondak VK, Thompson NT, Azab M, Lyons JF, Smalley KS and Wallis NG (2014). Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models. *Mol Cancer Ther* 13(12), 2793-804
- Shields L, Vega-Carrascal I, Singleton S, Lyng FM and McClean B (2014). Cell Survival and DNA Damage in Normal Prostate Cells Irradiated Out-of-Field. *Radiat Res* 182(5), 499-506

- Yu WD, Peng YF, Pan HD, Wang L, Li K and Gu J (2014). Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma. *World J Gastroenterol* 20(43), 16258-67
- Ghiazza M, Alloa E, Oliaro-Bosso S, Viola F, Livraghi S, Rembges D, Camomaccio R, Rossi F, Ponti J and Fenoglio I (2014). Inhibition of the ROS-mediated cytotoxicity and genotoxicity of nano-TiO₂ toward human keratinocyte cells by iron doping. *J Nanopart Res* (2014) 16, 2263
- Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R and Wang XS (2014). Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. *Nat Commun*. 2014 Aug 7; 5, 4577
- Venmar KT, Carter KJ, Hwang DG, Dozier EA and Fingleton B (2014). IL4 Receptor ILR4 α Regulates Metastatic Colonization by Mammary Tumors through Multiple Signaling Pathways. *Cancer Res* 74(16), 4329-40
- Piao HL, Yuan Y, Wang M, Sun Y, Liang H, and Ma L (2014). α -catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF- κ B signalling. *Nat Cell Biol*. 16(3), 245-54
- Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR and Boerner JL (2014). Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. *Breast Cancer Res Treat* 147(2), 283-93
- Li S, Kennedy M, Payne S, Kennedy K, Seewaldt VL, Pizzo SV and Bachelder RE (2014). Model of tumor dormancy/recurrence after short-term chemotherapy. *PLoS One* 9(5), e98021
- Singh R, Shankar BS, Sainis KB (2014). TGF- β 1-ROS-ATM-CREB signaling axis in macrophage mediated migration of human breast cancer MCF7 cells. *Cell Signal* 26(7), 1604-15
- Chini CC, Guerrero AM, Nin V, Camacho-Perera J, Escande C, Barbosa MT, Chini EN (2014). Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors. *Clin Cancer Res* 20(1), 120-30
- Berhane H, Epperly MW, Goff J, Kalash R, Cao S, Francicola D, Zhang X, Shields D, Houghton F, Wang H, Wipf P, Parmar K and Greenberger JS (2014). Radiologic differences between bone marrow stromal and hematopoietic progenitor cell lines from Fanconi Anemia (Fancd2(-/-)) mice. *Radiat Res* 181(1), 76-89
- Berhane H, Shinde A, Kalash R, Xu K, Epperly MW, Goff J, Francicola D, Zhang X, Dixon T, Shields D, Wang H, Wipf P, Li S, Gao X, Greenberger JS (2014). Amelioration of radiation-induced oral cavity mucositis and distant bone marrow suppression in fanconi anemia Fancd2(-/-) (FVB/N) mice by intraoral GS-nitroxide JP4-039. *Radiat Res* 182(1), 35-49
- Kalash R, Berhane H, Yang Y, Epperly MW, Wang H, Dixon T, Rhieu B, Greenberger JS and Huq MS (2014). Improved survival of mice after total body irradiation with 10 MV photon, 2400 MU/min SRS beam. *In Vivo* 28(1), 1-12
- Knubel KH, Pernu BM, Sufit A, Nelson S, Pierce AM and Keating AK (2014). MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. *Oncotarget* 5(5), 1338-51
- Foulkes JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner SB (2014). A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. *Neoplasia* 16(5), 403-12
- Hahm ER, Karlsson AI, Bonner MY, Arbisser JL, Singh SV (2014). Honokiol inhibits androgen receptor activity in prostate cancer cells. *Prostate* 74(4), 408-20
- Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, Goydos JS and Gorski DH (2014). Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. *PLoS One* 9(1), e81126
- Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owen P, Miller TW, Gómez H, Cook RS and Arteaga CL (2013). Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. *Cancer Res* 73(20), 6346-58
- Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L and Arteaga CL (2013). Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110 α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. *Cancer Res* 73(19), 6013-23
- Hanker AB, Pfeifferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS and Arteaga CL (2013). Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. *Proc Natl Acad Sci USA* 110(35), 14372-7
- Laurvak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA and Myklebost O (2013). Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. *Br J Cancer* 109(6), 2228-36
- Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Puzstai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC and Ueno NT (2013). TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. *Cancer Res* 73(21), 6516-25
- Covington KR, Brusco L, Barone I, Tsimelzon A, Selever J, Corona-Rodriguez A, Brown P, Kumar R, Hilsenbeck SG and Fuqua SA (2013). Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. *Breast Cancer Res Treat* 141(3), 375-384
- Cornelissen B, Waller A, Able S and Vallis KA (2013). Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γ H2AX. *Mol Cancer Ther* 12(11), 2472-82
- Andrianifahanana M, Wilkes MC, Gupta SK, Rahimi RA, Repellin CE, Edens M, Wittenberger J, Yin X, Maidl E, Becker J and Leaf EB (2013). Profibrotic TGF β responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. *FASEB J* 27(11), 4444-54
- Saud SM, Young MR, Jones-Hall YL, Ileva L, Ebuomwan MO, Wise J, Colburn NH, Kim Y and Sand Bobe G (2013). Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β -catenin. *Cancer Res* 73(17), 5473-84
- Gururaj AE, Gibson L, Panchabhai S, Bai M, Manyam G, Lu Y, Latha K, Rojas ML, Hwang Y, Liang S and Bogler O (2013). Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of Δ EGFR/EGFRvIII. *J Biol Chem* 288(5), 3428-38
- Cabarcas SM, Sun L, Mathews L, Thomas S, Zhang X and Farrar WL (2013). The Differentiation of Pancreatic Tumor-Initiating Cells by Vitronectin Can Be Blocked by Cilengitide. *Pancreas* 42(5), 861-70
- Garrett JT, Sutton CR, Kuba MG, Cook RS and Arteaga CL (2013). Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. *Clin Cancer Res* 19(3), 610-9
- Beckler MD, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M, Liebler DC and Coffey RJ (2013). Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. *Mol Cell Proteomics* 12(2), 343-55
- Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinhu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB and Brown PH (2013). Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8. *Cancer Res* 73(11), 3470-80
- Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Chistiakova L, Abraham RT and Gerber HP (2013). Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. *Mol Cancer Ther* 12(1), 38-47
- Bianco C, Castro NP, Baraty C, Rollman K, Held N, Rangel MC, Karasawa H, Gonzales M, Strizzi L and Salomon DS (2013). Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells. *J Cell Physiol* 228(6), 1174-88
- Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, Deryckere D and Graham DK (2013). Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. *Oncogene* 32(46):5359-68
- Onnis B, Fer N, Rapisarda A, Perez VS and Melillo G (2013). Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. *J Clin Invest* 123(4), 1615-29
- Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T and Stokoe D (2013). Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. *J Biol Chem* 288(4), 2403-13
- Krishnan M, Lapierre LA, Knowles BC and Goldenring JR (2013). Rab25 regulates integrin expression in polarized colonic epithelial cells. *Mol Biol Cell* 24(6), 818-31
- Stratford EW, Bostad M, Castro R, Skarpen E, Berg K, Høget S, Myklebost O and Selbo PK (2013). Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity. *Biochim Biophys Acta* 1830(8), 4235-43
- Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, Young MR, Klarmann KD, Keller JR and Farrar WL (2013). Epigenetic Regulation of SOX9 by the NF- κ B Signaling Pathway in Pancreatic Cancer Stem Cells. *Stem Cells*. 31(8), 1454-66
- Barrett CW, Ning W, Chen X, Smith JJ, Washington MK, Hill KE, Coburn LA, Peek RM, Chaturvedi R, Wilson KT, Burk RF and Williams CS (2013). Tumor suppressor function of the plasma glutathione peroxidase gpX3 in colitis-associated carcinoma. *Cancer Res* 73(3), 1245-55
- Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM and Stokoe D (2013). A requirement for wild-type Ras isoforms in mutant KRAS-driven signaling and transformation. *Biochem J* 452(2), 313-20
- De Robertis A, Valensin S, Rossi M, Tunici P, Verani M, De Rosa A, Giordano C, Varrone M, Nencini A, Pratelli C, Benicchi T, Bakker A, Hill J, Sanghongpitak K, Pendharkar V, Liu B, Ng FM, Then SW, Tai SJ, Cheong SM, He X, Caricasole A and Salerno M (2013). Identification and characterization of a small molecule inhibitor of Wnt signaling in glioblastoma cells. *Mol Cancer Ther*. 12(7), 1180-9
- Brandao LN, Wings A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D and Graham DK (2013). Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. *Blood Cancer J*. 3:e101
- Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN and Ueno NT (2013). Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP. *Mol Cancer Ther* 12(6), 1099-111
- Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK and Keyomarsi K (2013). Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. *Cancer Res* 73(17), 5556-68
- Sandberg CJ, Altschuler G, Jeong J, Stramme KK, Stangeland B, Murrell W, Grasmow-Wendler UH, Myklebost O, Helseth E, Vik-Mo EO, Hide W and Langmoen IA (2013). Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. *Exp Cell Res* 319(14), 2230-43
- Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC and Arteaga CL (2013). Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survival axis and are sensitive to PI3K inhibitors. *Cancer Res*. 73(3), 1190-200
- Arai K, Sakamoto R, Kubota D and Kondo T (2013). Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. *Proteomics* 13(15), 2351-60
- B Gungor, P Owens and HL Moses (2013). Uncovering the Role of TGF β and BMP in Triple Negative Breast Cancer Stem Cells. *Young Scientists Journal*. 3
- Rolseth V, Krokeide SZ, Kunke D, Neurauder CG, Suganthan R, Sejersted Y, Hildrestrand GA, Bjørås M and Luna L (2013). Loss of Neil3, the major DNA glycosylase activity for removal of hydantoins in single stranded DNA, reduces cellular proliferation and sensitizes cells to genotoxic stress. *Biochim Biophys Acta* 1833(5), 1157-64
- Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paraniham J, Hayes DF, Wicha MS and Chang JC (2013). Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. *Clin Cancer Res* 19(6), 1512-24
- Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS and Arteaga CL (2013). TGF- β inhibition enhances chemotherapy action against triple-negative breast cancer. *J Clin Invest* 123(3), 1348-58
- Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN and Sawyers CL (2013). Androgen receptor signaling regulates DNA repair in prostate cancers. *Cancer Discov* 3(11), 1245-53
- Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandão LN, Wings A, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS and Graham DK (2013). Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. *Blood*, 122(9), 1599-609
- Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M, Epperly M and Levina V (2013). Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. *Mol Cancer* 12(1), 94
- Epperly MW, Chaillet JR, Kalash R, Shaffer B, Goff J, Francicola D, Zhang X, Dixon T, Houghton F, Wang H, Berhane H, Romero C, Kim JH and Greenberger JS (2013). Conditional radioresistance of Tg-inducible manganese superoxide dismutase bone marrow stromal cell lines. *Radiat Res* 180(2), 189-204
- Kaur G, Behrsing H, Parchment RE, Millin MD and Teicher BA (2013). Analyses of the combination of 6-MP and dasatinib in cell culture. *Int J Oncol* 43(1), 13-22
- Krishnan M, Lapierre LA, Knowles BC and Goldenring JR (2013). Rab25 regulates integrin expression in polarized colonic epithelial cells. *Mol Biol Cell* 24(6), 818-31
- Shelton JW, Waxweiler TV, Landry J, Gao H, Xu Y, Wang L, El-Rayes B and Shu HK (2013). In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells. *Int J Radiat Oncol Biol Phys* 86(3), 469-76
- Kaur G, Behrsing H, Parchment RE, Millin MD and Teicher BA (2013). Analyses of the combination of 6-MP and dasatinib in cell culture. *Int J Oncol* 43(1), 13-22
- Singh B, Bogatcheva G, Washington MK and Coffey RJ (2013). Transformation of polarized epithelial cells by apical mistrafficking of epi-regulin. *Proc Natl Acad Sci USA* 110(22), 8960-5

- Fenoglio I, Ponti J, Alloa E, Ghiazza M, Corazzari I, Capomaccio R, Rembges D, Oliaro-Bosso S and Rossi F (2013). Singlet oxygen plays a key role in the toxicity and DNA damage caused by nanometric TiO₂ in human keratinocytes. *Nanoscale* 5(14), 6567-76
- Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak S, Munthe E and Myklebost O (2012). Characterization of liposarcoma cell lines for preclinical and biological studies. *Sarcoma* 2012:148614
- Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schultz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P and Jen J (2012). Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. *Clin Cancer Res* 18(13), 3658-67
- Gupta SK, Oommen S, Aubry MC, Williams BP and Vlahakis NE (2012). Integrin α9β1 promotes malignant tumor growth and metastasis by potentiating epithelial-mesenchymal transition. *Oncogene* 32(2), 141-50
- Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL and Yang ZQ (2012). Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. *Am J Transl Res* 4(3), 247-256
- Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Lador US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF and Shoemaker AR (2012). Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. *Clin Cancer Res* 18(2), 510-23
- Regnell CE, Hildrestrand GA, Sejersted Y, Medin T, Moldestad O, Rolseth V, Krokeide SZ, Suganthan R, Luna L, Bjørås M and Bergersen LH (2012). Hippocampal adult neurogenesis is maintained by nei3-dependent repair of oxidative DNA lesions in neural progenitor cells. *Cell Rep* 2(3), 503-10
- Wang C, Mayer JA, Mazumdar A and Brown PH (2012). The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. *Breast Cancer Res Treat* 133(2), 487-500
- Hurst NJ, Najj AJ, Ustach CV, Movilla L and Kim HR (2012). Platelet-derived growth factor-C (PDGFC) activation by serine proteases: implications for breast cancer progression. *Biochem J* 441(3), 909-18
- Wang C, Mayer JA, Mazumdar A and Brown PH (2012). The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. *Breast Cancer Res* 133(2), 487-500
- Cho YM, Kim YS, Kang MJ, Farrar WL and Hurt EM (2012). Long-term recovery of irradiated prostate cancer increases cancer stem cells. *Prostate* 72, 1746-1756
- Cabarcas SM, Thomas S, Zhang X, Cherry JM, Sebastian T, Yerramilli S, Lader E, Farrar WL, Hurt EM (2012). The role of upregulated miRNAs and the identification of novel mRNA targets in prostatospheres. *Genomics* 99(2), 108-17
- Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K and Boerner JL (2012). Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. *Breast Cancer Res* 14(4), R104
- Cerna D, Li H, Flaherty S, Takebe N, Coleman CN and Yoo SS (2012). Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAMPT1)-dependent manner. *J Biol Chem* 287(26), 22408-17
- Bhattacharya R, Wang E, Dutta SK, Vohra PK, E G, Prakash YS and Mukhopadhyay D (2012). NHERF-2 maintains endothelial homeostasis. *Blood* 119(20), 4798-806
- O'Sullivan RP, Greenberger JS, Goff J, Cao S, Kingston KA, Zhou S, Dixon T, Houghton FD, Epperly MW, Wang H and Glowacki J (2012). Dysregulated in vitro hematopoiesis, radiosensitivity, proliferation, and osteoblastogenesis with marrow from SAMP6 mice. *Exp Hematol* 40(6), 499-509
- Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinks J and Tibbitts J (2012). The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. *Mol Cancer Ther* 11(5), 1133-42
- Kessel DH, Price M and Reiners JJ Jr (2012). ATG7 deficiency suppresses apoptosis and cell death induced by lysosomal photodamage. *Autophagy* 8(9), 1333-41
- Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA and Woodward WA (2012). Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. *Breast Cancer Res Treat* 134(2), 495-510
- Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN and Basik M (2011). An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. *Oncogene* 31(16), 2090-2100
- Ferruzzi P, Mennillo F, De Rosa A, Giordano C, Rossi M, Benedetti G, Magrini R, Mohr GL, Miragliotta V, Magnoni L, Mori E, Thomas R, Tunici P and Bakker A (2011). In vitro and in vivo characterization of a novel hedgehog signaling antagonist in human glioblastoma cell lines. *Int J Cancer* 131(2), E33-44
- Selever J, Gu G, Lewis MT, Beyer A, Herynk MH, Covington KR, Tsimelzon A, Dontu G, Provost P, Di Pietro A, Boumendjel A, Albain K, Miele L, Weiss H, Barone I, Ando S, and Fuqua SA (2011). Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. *Clin Cancer Res* 17(20), 6510-21
- Lapierre LA, Caldwell CM, Higginbotham JN, Avant KM, Hall J, Beauchamp RD and Goldenring JR (2011). Transformation of rat intestinal epithelial cells by overexpression of Rab25 is microtubule dependent. *Cytoskeleton (Hoboken)* 68(2), 97-111
- Baillo A, Giroux C and Ethier SP (2011). Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. *J Cell Physiol* 226(10), 2691-701
- Dhawani P, Ahmad R, Chaturvedi R, Smith JJ, Midha R, Mittal MK, Krishnan M, Chen X, Eschrich S, Yeatman TJ, Harris RC, Washington MK, Wilson KT, Beauchamp RD and Singh AB (2011). Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. *Oncogene* 30(29) 3234-47
- Florey O, Kim SE, Sandoval CP, Haynes CM and Overholtzer M (2011). Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes. *Nat Cell Biol* 13(11), 1335-43
- Koh MY, Lemos R Jr, Liu XP and Powis G (2011). The hypoxia associated factor (HAF) switches cells from HIF-1 α to HIF-2 α dependent signalling promoting stem cell characteristics, aggressive tumor growth and invasion. *Cancer Res* 71(11), 4015-27
- Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE, Danesi R and Farrar WL (2011). Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. *Mol Cancer* 10(1), 40
- Espinoza I, Liu H, Busby R and Lupu R (2011). CCN1 is a candidate target for zoledronic acid treatment in breast cancer. *Mol Cancer Ther* 10(5), 732-41
- Andrzejak M, Marie Santiago M, and Kessel D (2011). Effects of endosomal photodamage on membrane recycling and endocytosis. *Photochem Photobiol* 87(3), 699-706
- Kessel D (2011). Inhibition of endocytic processes by photodynamic therapy. *Lasers Surg Med* 43(7), 542-7
- Woolston C and Martin S (2011). Analysis of tumor and endothelial cell viability and survival using sulforhodamine B and clonogenic assays. *Methods Mol Biol* 740, 45-56
- Z Kan, BS Jaiswal, J Stinson, V Janakiraman, et al. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. *Nature* 466, 869-873
- Dong J, Sereno A, Snyder WB, et al. (2010). Stable IgG-like bispecific antibodies directed towards the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. *J Biol Chem* 286(6), 4703-17
- Andl CD, McCowan KM, Allison GL, Rustgi AK (2010). Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. *Neoplasia* 12(6), 485-498
- Liu XJ, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z and Plunkett W (2010). Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. *Blood* 116(10), 1737-1746
- Andrianifahanana M, Wilkes MC, Repellin CE, Edens M, Kottom TJ, Rahimi RA and Leaf EB. (2010). ERBB receptor activation is required for profibrotic responses to transforming growth factor beta. *Cancer Research* 70(19), 7421-30
- Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD and Sawyers CL (2010). ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. *Nature* 467(7317), 849-53
- Yao S et al. (2010). PRKC-ζ expression promotes the aggressive phenotype of human prostate cancer cells and is a novel target for therapeutic intervention. *Genes & Cancer*, 1(5), 444-464
- Heyerdahl SL, Rozenberg J, Jamtgaard L, Rishi V, Varticovskie L, Akah K, Scudiero D, Shoemaker RH, Karpova TS, Day RN, McNally JG and Vinson C (2010). The arylsibononic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. *Eur J Cell Biology* 89 (7), 564-573
- Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, and Sawyers CL (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. *Proc Natl Acad Sci USA*. 107(39), 16759-16765
- Robertson FM, Woodward WA, Pickei R, Ye Z, Bornmann W, Pal A, Peng Z, Hall CS, and Cristofanilli M (2010). Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. *Cancer* 116(S11), 2760 - 2767
- Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M and Barsky SH (2010). Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. *Journal of Biomolecular Screening*. 15(7), 820-9
- Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT and Woodward WA (2010). Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. *Molecular Cancer* 9, 180
- Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M and Woodward WA (2010). Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. *Int J Rad Onc* 76(3), 889-895
- Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X and Farrar WL (2010). Genomic profiling of tumor initiating prostatospheres. *BMC Genomics* 11, 324-340
- Woodward WA, Debeb BG, Xu W and Buchholz TA (2010). Overcoming radiation resistance in inflammatory breast cancer. *Cancer* 116 (S11), 2840-2845
- Jaiswal BS et al. (2009). Somatic mutations in p85α promote tumorigenesis through Class IA PI3K activation. *Cancer Cell* 16, 463-474
- Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ and Levin VA (2009). Melding a new 3-dimensional agarose colony assay with the E(max) model to determine the effects of drug combinations on cancer cells. *Technol Cancer Res Treat* 8, 163-176
- Wilkes MC, Repellin CE, Hong M, Bracamonte M, Penheiter SG, Borg J-P, and Leaf EB (2009). Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-β. *Developmental Cell* 16, 433-444
- Dave B, Lewis M and Chang J (2009). Lentiviral shRNA screen to test the validity of a gene signature of breast cancer stem cells using high throughput mammosphere assays. *Cancer Res* 69 (24 Suppl), Abstract nr 1158
- Kajiwara Y, Panchabhai S and Levin VA (2008). A new preclinical 3-dimensional agarose colony formation assay. *Technol Cancer Res Treat* 7, 329-334